AstraZeneca, Daiichi Will Seek Approval Following ADC Trial Success In Advanced Breast Cancer
• By Sten Stovall
Trastuzumab deruxtecan showed a clinically-meaningful response rate in patients with refractory HER2-positive metastatic breast cancer. • Source: Shutterstock
Keep up with the top pharma business news of the week. On the go.
